Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy : vimarsana.com

SEATTLE, July 28, 2023 -- Chinook Therapeutics, Inc. , a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today...

Related Keywords

Noopur Liffick , Eric Dobmeier , Vlado Perkovic , University Of New South Wales , Globenewswire Inc , Investor Relations Corporate Communications Media Contact , Chinook Therapeutics Inc , Exchange Commission , Novartis , Investor Relations Corporate Communications , Nasdaq , New South Wales , About Chinook Therapeutics , Definitive Proxy Statement , Current Reports , Annual Report , Quarterly Reports , Securities Act , Definitive Proxy , Novartis Annual Report , Vice President , Investor Relations , Corporate Communications , Media Contact , North Senior Manager ,